The first five years of SARS-CoV-2: inpatient treatment updates and future directions
- 21 September 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (14) , 1873-1878
Abstract
Introduction In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in adults with pneumonia in Wuhan, China. Areas covered It is now believed that several billion humans have been infected with SARS-CoV-2 and more than ten million have died from coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2. Expert opinion The first five years of the SARS-CoV-2 pandemic have been marked by unfathomable suffering as well as remarkable scientific progress. This manuscript examines what has been learned about the treatment of inpatients with COVID-19 and explores how the therapeutic approach may evolve in the years ahead.Keywords
This publication has 68 references indexed in Scilit:
- Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19JAMA Network Open, 2024
- Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 PneumoniaJAMA, 2023
- Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19JAMA, 2023
- Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical TrialJAMA, 2023
- Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19JAMA, 2022
- Identification of Drug Interaction Adverse Events in Patients With COVID-19JAMA Network Open, 2022
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19JAMA, 2020
- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)JAMA, 2020